Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

Interferon Α ◽

Multicenter Phase

Interleukin-2 (IL-2), interferon-α (IFN- α), 5-fluorouracil (5-FU) and vinblastine (VBL) for treatment of metastatic renal cell carcinoma (MRCC). A prospective phase II study

10.1200/jco.2004.22.90140.4671 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4671-4671

Author(s):

R. Rubinov ◽

E. Gez ◽

N. Haim ◽

A. Kuten ◽

S. Meritick

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

Interferon Α ◽

Prospective Phase

Interleukin-2 (IL-2), interferon-α (IFN- α), 5-fluorouracil (5-FU) and vinblastine (VBL) for treatment of metastatic renal cell carcinoma (MRCC). A prospective phase II study

10.1200/jco.2004.22.14_suppl.4671 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4671-4671

Author(s):

R. Rubinov ◽

E. Gez ◽

N. Haim ◽

A. Kuten ◽

S. Meritick

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

Interferon Α ◽

Prospective Phase

Subcutaneous Recombinant Interleukin-2 and a-Interferon in Patients with Advanced Renal Cell Carcinoma: Results of a Multicenter Phase II Study

Cancer Biotherapy ◽

10.1089/cbr.1993.8.289 ◽

1993 ◽

Vol 8 (4) ◽

pp. 289-300 ◽

Cited By ~ 9

Author(s):

Jens Atzpodien ◽

Hartmut Kirchner ◽

Peter de Mulder ◽

Heiner Bodenstein ◽

Tim Olivera ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

Advanced Renal Cell Carcinoma ◽

Multicenter Phase ◽

Recombinant Interleukin 2

Interferon-α, 5-FU and prednisone in metastatic renal cell carcinoma: A phase II study

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058801 ◽

1994 ◽

Vol 5 (3) ◽

pp. 245-248 ◽

Cited By ~ 18

Author(s):

H. Haarstad ◽

A.-B. Jacobsen ◽

S.A. Schjølseth ◽

T. Risberg ◽

S.D. Fosså

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interferon Α

Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study

European Journal of Cancer and Clinical Oncology ◽

10.1016/0277-5379(91)90419-e ◽

1991 ◽

Vol 27 (12) ◽

pp. 1583-1589 ◽

Cited By ~ 37

Author(s):

H. von der Maase ◽

P. Geertsen ◽

N. Thatcher ◽

C. Jasmin ◽

A. Mercatello ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

Multicentre Phase ◽

Recombinant Interleukin 2

Efficacy of sorafenib in combination with gemcitabine and fluorouracil in metastatic renal-cell carcinoma: Preliminary result of a multicenter phase II study.

10.1200/jco.2011.29.15_suppl.e15042 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e15042-e15042

Author(s):

J. Guo ◽

C. L. Cui ◽

H. Chen ◽

X. D. Xie ◽

J. Chen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Multicenter Phase

A randomized phase II trial of interleukin-2/interferon-α plus bevacizumab versus interleukin-2/interferon-α in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1.

10.1200/jco.2016.34.15_suppl.4563 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4563-4563 ◽

Cited By ~ 4

Author(s):

Frede Donskov ◽

Niels Viggo Jensen ◽

Torben Smidt-Hansen ◽

Line Brondum ◽

Poul F. Geertsen

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Interleukin 2 ◽

Interferon Α ◽

Cancer Group ◽

Randomized Phase Ii

A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

Journal of Immunotherapy ◽

10.1097/cji.0000000000000003 ◽

2013 ◽

Vol 36 (9) ◽

pp. 490-495 ◽

Cited By ~ 19

Author(s):

Uday B. Dandamudi ◽

Musie Ghebremichael ◽

Jeffrey A. Sosman ◽

Joseph I. Clark ◽

David F. McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

High Dose

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

Acta Oncologica ◽

10.1080/0284186x.2018.1433324 ◽

2018 ◽

Vol 57 (5) ◽

pp. 589-594 ◽

Cited By ~ 5

Author(s):

Frede Donskov ◽

Niels Viggo Jensen ◽

Torben Smidt-Hansen ◽

Line Brøndum ◽

Poul Geertsen

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Phase Ii Trial ◽

Interleukin 2 ◽

Interferon Α ◽

Cancer Group ◽

Randomized Phase Ii

A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma

Cancer Immunology Immunotherapy ◽

10.1007/s002620050393 ◽

1997 ◽

Vol 44 (6) ◽

pp. 348-351 ◽

Cited By ~ 6

Author(s):

A. Piga ◽

Paolo Giordani ◽

Agata Quattrone ◽

Marco Giulioni ◽

Giorgio De Signoribus ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Low Dose ◽

Phase Ii Study ◽

Interleukin 2 ◽

Advanced Renal Cell Carcinoma ◽

Interferon Α